GLP1R and type 2 diabetes mellitus: The rationale for development of DPP4 inhibitors for the therapy of T2D was largely based on findings that DPP4 inactivated GLP-1 and GIP, whereas inhibition of the enzyme stabilised levels of active incretin hormones and enhanced glucose homeostasis1,3,47,48.